GleamWall
中文EN

SRPT Sarepta Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 873303 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-18.9%
TTM net income YoY19.4%
TTM EPS YoY19.9%
Revenue 3-yr CAGR21.0%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-2.5%
Net margin-5.9%
FCF margin9.0%
EBITDA margin-0.9%

Returns

ROE-7.6%
ROA-3.4%
ROIC (approx.)-2.5%
Asset turnover0.59x

Leverage & solvency

Liabilities / assets51.7%
Debt / equity0.66x
Current ratio3.46x
Interest coverage0.62x

Cash quality & payout

Operating cash flow / net income-1.62x
Accruals ratio-9.0%
Payout ratio—
Capex / revenue0.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q42025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q42024-12-31
Income statement
Revenue$381.35M$401.25M$730.80M$442.93M$399.36M$611.09M$744.86M$658.41M
Gross profit———-$29.10M$219.27M$360.56M$473.96M$505.85M
R&D expense$82.55M$91.26M$153.96M$325.34M$218.89M$204.39M$773.45M$199.95M
SG&A expense$118.61M$107.60M$108.95M$128.30M$91.89M$137.90M$133.63M$163.87M
Operating income-$9.04M$13.29M$358.43M-$411.58M-$103.39M$115.58M-$300.39M$161.68M
Interest expense$21.62M-$21.51M-$21.71M-$57.33M$9.46M-$5.23M-$4.50M-$32.31M
Pretax income-$25.77M-$1.75M$343.17M-$407.68M-$64.67M$153.64M-$383.52M$171.74M
Income tax$2.69M$3.14M$12.21M$4.55M-$14.10M-$43.25M$63.99M$12.69M
Net income-$28.46M-$4.89M$330.96M-$412.23M-$50.57M$196.89M-$447.51M$159.05M
EBITDA-$3.14M$23.70M$369.03M-$406.33M-$84.94M$126.42M-$290.41M$172.14M
EPS (basic)-0.27-0.053.15-3.93-0.502.01-4.601.65
EPS (diluted)-0.27-0.052.88-3.93-0.501.89-4.601.50
Weighted avg. shares (diluted)105.93M105.43M121.92M—100.24M106.62M97.36M—
Balance sheet
Cash & equivalents$472.76M$571.15M$464.45M$801.28M$613.08M$510.60M$240.87M$1.12B
Short-term investments$406.02M$217.34M$188.74M$138.37M$237.92M$289.54M$281.89M$251.78M
Receivables$369.18M$376.82M$394.82M$398.23M$395.74M$527.29M$659.37M$601.99M
Inventory$876.12M$904.27M$1.00B$914.74M$1.08B$994.04M$941.43M$749.96M
Current assets$2.27B$2.22B$2.31B$2.54B$2.72B$2.66B$2.43B$3.07B
PP&E, net$319.29M$325.99M$336.24M$345.12M$358.94M$371.86M$360.59M$340.34M
Intangibles$29.83M$30.61M$31.38M$28.95M$29.68M$30.52M$26.20M$26.89M
Total assets$3.17B$3.19B$3.18B$3.35B$3.49B$3.68B$3.47B$3.96B
Current liabilities$656.35M$502.91M$499.16M$1.10B$921.42M$919.95M$605.59M$731.68M
Short-term debt$157.97M——$0———$0
Long-term debt$857.36M$847.62M$838.16M$828.97M$140.50M——$1.14B
Total debt$1.02B$847.62M$838.16M$828.97M$140.50M——$1.14B
Total liabilities$1.64B$1.66B$1.67B$2.21B$2.17B$2.32B$2.32B$2.44B
Shareholders' equity$1.53B$1.53B$1.51B$1.14B$1.50B$1.40B$1.19B$1.53B
Net debt$542.58M$276.48M$373.71M$27.69M-$472.58M——$18.54M
Shares outstanding107.23M105.62M105.57M104.96M104.77M97.71M98.25M96.90M
Cash flow statement
Operating cash flow$59.97M$197.07M-$202.68M$131.21M-$14.59M$261.34M-$583.44M$92.05M
Capital expenditure$2.93M$555,000$2.08M$3.59M$22.93M$31.80M$43.65M$38.08M
Free cash flow$57.03M$196.51M-$204.76M$127.61M-$37.52M$229.54M-$627.09M$53.96M
Investing cash flow-$158.35M-$93.37M-$134.39M$96.21M$232.40M$32.21M-$291.18M$764.12M
Financing cash flow$0$0$241,000-$39.21M-$117.79M-$23.82M$12.47M$48.99M
Depreciation & amortization$5.90M$10.41M$10.59M$5.25M$18.45M$10.84M$9.98M$10.46M
Stock-based compensation$26.70M$24.50M$29.40M$30.02M$14.90M$37.00M$41.43M$49.68M
Share buybacks———$0$0——$0

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.